{"id":"https://openalex.org/W4361813729","doi":"https://doi.org/10.1158/1078-0432.22482984.v1","title":"Supplementary Figure from Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer","display_name":"Supplementary Figure from Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361813729","doi":"https://doi.org/10.1158/1078-0432.22482984.v1"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22482984.v1","doi":"https://doi.org/10.1158/1078-0432.22482984.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22482984.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_from_Determinants_of_Response_to_Talazoparib_in_Patients_with_HER2-Negative_Germline_i_BRCA1_2_i_-Mutated_Breast_Cancer/22482984/1/files/39934515.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_from_Determinants_of_Response_to_Talazoparib_in_Patients_with_HER2-Negative_Germline_i_BRCA1_2_i_-Mutated_Breast_Cancer/22482984/1/files/39934515.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042123072","display_name":"Joanne Lorraine Blum","orcid":"https://orcid.org/0000-0002-7951-6645","observed_orcids":["https://orcid.org/0000-0002-7951-6645"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joanne L. Blum","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087379820","display_name":"Alexander Laird","orcid":"https://orcid.org/0000-0002-7296-025X","observed_orcids":["https://orcid.org/0000-0002-7296-025X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Douglas Laird","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014713051","display_name":"Jennifer Keating Litton","orcid":"https://orcid.org/0000-0001-8390-4985","observed_orcids":["https://orcid.org/0000-0001-8390-4985"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer K. Litton","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090188675","display_name":"Hope S. Rugo","orcid":"https://orcid.org/0000-0001-6710-4814","observed_orcids":["https://orcid.org/0000-0001-6710-4814"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hope S. Rugo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048706345","display_name":"Johannes Ettl","orcid":"https://orcid.org/0000-0003-4754-8447","observed_orcids":["https://orcid.org/0000-0003-4754-8447"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Johannes Ettl","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068059897","display_name":"Sara Alsterlind Hurvitz","orcid":"https://orcid.org/0000-0001-7808-7191","observed_orcids":["https://orcid.org/0000-0001-7808-7191"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sara A. Hurvitz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100671433","display_name":"Miguel Mart\u00edn","orcid":"https://orcid.org/0000-0001-9237-3231","observed_orcids":["https://orcid.org/0000-0001-9237-3231"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Miguel Martin","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9237-3231","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052648400","display_name":"Henri Hubert Roche","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Henri H. Roch\u00e9","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101886232","display_name":"Kyung-Hun Lee","orcid":"https://orcid.org/0000-0002-2390-3240","observed_orcids":["https://orcid.org/0000-0002-2390-3240"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kyung-Hun Lee","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2390-3240","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015645119","display_name":"Annabel Goodwin","orcid":"https://orcid.org/0000-0002-8859-9980","observed_orcids":["https://orcid.org/0000-0002-8859-9980"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Annabel Goodwin","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8859-9980","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100383140","display_name":"Ying Chen","orcid":"https://orcid.org/0009-0005-8351-6620","observed_orcids":["https://orcid.org/0009-0005-8351-6620"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ying Chen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017925719","display_name":"Silvana Lanzalone","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Silvana Lanzalone","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082203887","display_name":"Jijumon Chelliserry","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jijumon Chelliserry","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050035884","display_name":"Akos Gabor Czibere","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Akos Czibere","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111984953","display_name":"Julia F. Hopkins","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Julia F. Hopkins","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020251022","display_name":"Lee A. Albacker","orcid":"https://orcid.org/0000-0002-5070-1783","observed_orcids":["https://orcid.org/0000-0002-5070-1783"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lee A. Albacker","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5070-1783","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5070265480","display_name":"Lida A. Mina","orcid":"https://orcid.org/0000-0003-2606-9922","observed_orcids":["https://orcid.org/0000-0003-2606-9922"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lida A. Mina","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2606-9922","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9868000149726868,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9868000149726868,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.013100000098347664,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/talazoparib","display_name":"talazoparib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.7590000033378601},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.9319999814033508},{"id":"https://openalex.org/keywords/germline-brca1-mutation","display_name":"germline BRCA1 mutation","score":0.9419999718666077},{"id":"https://openalex.org/keywords/germline-brca2-mutation","display_name":"germline BRCA2 mutation","score":0.9990000128746033},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.7599999904632568},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.9490000009536743}],"concepts":[{"id":"https://openalex.org/C109825262","wikidata":"https://www.wikidata.org/wiki/Q1139164","display_name":"Germline","level":3,"score":0.8134089708328247},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6915553212165833},{"id":"https://openalex.org/C13514818","wikidata":"https://www.wikidata.org/wiki/Q5552256","display_name":"Germline mutation","level":4,"score":0.5017030239105225},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4419209063053131},{"id":"https://openalex.org/C2910363380","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"HER2 negative","level":5,"score":0.41610994935035706},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.40951618552207947},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.39099758863449097},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3683866262435913},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.35770994424819946},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.27355581521987915},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.2230508029460907},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.20183858275413513},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.13155004382133484},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0830533504486084}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.22482984.v1","doi":"https://doi.org/10.1158/1078-0432.22482984.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22482984.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_from_Determinants_of_Response_to_Talazoparib_in_Patients_with_HER2-Negative_Germline_i_BRCA1_2_i_-Mutated_Breast_Cancer/22482984/1/files/39934515.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22482984","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_from_Determinants_of_Response_to_Talazoparib_in_Patients_with_HER2-Negative_Germline_i_BRCA1_2_i_-Mutated_Breast_Cancer/22482984","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22482984.v1","doi":"https://doi.org/10.1158/1078-0432.22482984.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22482984.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_from_Determinants_of_Response_to_Talazoparib_in_Patients_with_HER2-Negative_Germline_i_BRCA1_2_i_-Mutated_Breast_Cancer/22482984/1/files/39934515.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361813729.pdf","grobid_xml":"https://content.openalex.org/works/W4361813729.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4210415729","https://openalex.org/W2947158665","https://openalex.org/W4361813962","https://openalex.org/W4360601200","https://openalex.org/W3173061082","https://openalex.org/W4213321903","https://openalex.org/W4306411819","https://openalex.org/W4399636237","https://openalex.org/W3011377044","https://openalex.org/W3129192144"],"abstract_inverted_index":{"Supplementary":[0],"Figure":[1],"from":[2],"Determinants":[3],"of":[4],"Response":[5],"to":[6],"Talazoparib":[7],"in":[8],"Patients":[9],"with":[10],"HER2-Negative,":[11],"Germline":[12],"BRCA1/2-Mutated":[13],"Breast":[14],"Cancer":[15]},"counts_by_year":[],"updated_date":"2026-10-10T09:11:00.788812","created_date":"2023-04-05T00:00:00"}